Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Concept

Cancer immunology

Publications associées (31)

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Ali Ghasemi

Dendritic cells (DCs) are specialized myeloid cells with the ability to uptake, process, and present antigens to T lymphocytes. They also generate cytokine and chemokine gradients that regulate immune cell trafficking, activation, and function. Monocyte-de ...

EPFL2024

Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Aaron Simone Petruzzella

Cysteine cathepsins proteases are enzymes that play essential physiological roles, but their activity is also associated to different aspects of cancer progression and to the development of other diseases. Therefore, cysteine cathepsins are relevant and pr ...

EPFL2024

An autologous antigen-agnostic dendritic cell therapy that forgoes antigen loading

Michele De Palma

We developed a method for generating dendritic cell progenitors (DCPs) from hematopoietic stem and progenitor cells isolated from bone marrow or blood. When engineered to express IL-12 and FLT3L, these DCPs reprogram the tumor microenvironment and elicit a ...

Nature Portfolio2024

Exploration and modulation of mechanical cues for enhanced cancer immunotherapy

Armand Kurum

The advent of immunotherapy, such as immune checkpoint blockade (ICB) and adoptive transfer of cytotoxic lymphocytes, has transformed the clinical care of cancer. However, a significant proportion of patients are resistant to immunotherapy or experience re ...

EPFL2024

Elucidating and modulating regulatory pathways so as to reprogram the immunosuppressive tumor microenvironment for therapeutic benefit

Agnieszka Alicja Chryplewicz

Glioblastoma (GBM) is the most frequent and highly malignant form of brain cancer. New therapeutic regimens are urgently needed as GBM patients present with a minimal response to currently-approved therapies. The goal of this project is to identify new the ...

EPFL2023

Highly effective adoptive t cell therapy

Li Tang, Yugang Guo, Bing Feng

The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions ...

2023

Hyperthermic intrathoracic chemotherapy to control malignant pleural mesothelioma

Yameng Hao

OBJECTIVE: Malignant pleural mesothelioma (MPM) is a rare disease that has a poor response to conventional therapy. Hyperthermic intrathoracic chemotherapy (HITOC), a treatment combining fever-range hyperthermia with intrapleural cisplatin chemotherapy, ha ...

EPFL2023

Cgas super-enzymes for cancer immunotherapy

Andrea Ablasser, Natasha Ella Samson, Alexander Scott Keller

The present invention relates to anti-tumor lymphocytes, and a variant cyclic GMP-AMP synthase (cGAS) carrying an amino acid substitution of one or both arginines at amino acid positions 255 and 236 and/or an amino acid substitution of one or both lysines ...

2023

Tracking spatiotemporal localisation and interactions of the innate immune sensor STING

Sophie Marie Elisabeth Rivara

Innate immunity, the very first line of defence of our cells, relies on the detection of universal pathogen- or danger-associated signals to launch an inflammatory response. A crucial part of our innate immune system is based on the recognition of out-of-c ...

EPFL2023

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Jaume Bonet Martinez

Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates are urgently ne ...

TAYLOR & FRANCIS INC2023

Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation

Andrea Ablasser

Solid cancers exhibit a dynamic balance between cell death and proliferation ensuring continuous tumour maintenance and growth(1,2). Increasing evidence links enhanced cancer cell apoptosis to paracrine activation of cells in the tumour microenvironment in ...

NATURE PORTFOLIO2022

Dendritic cell cross-dressing and tumor immunity

Michele De Palma, Amaia Martinez Usatorre

In addition to direct and cross-presentation, dendritic cells (DCs) can present tumor antigens (TAs) to T cells via a hitherto poorly understood mechanism called "cross-dressing." DC cross-dressing involves the acquisition of preformed peptide-major histoc ...

WILEY2022

Immunosuppressive roles of Activin-A in melanoma and characterization of its precursor cleavage

Katarina Pinjusic

Activin-A, a transforming growth factor ê µ family member, is a pleiotropic cytokine with diverse functions in development, fertility, adult tissue homeostasis, and aging. Accordingly, deregulation of Activin-A signaling has been associated with many patho ...

EPFL2022

Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy

Pénélope Andreux

T memory stem cells (T-SCM) display increased self-renewal and prolonged survival capabilities, thus preventing T cell exhaustion and promoting effective anti-tumor T cell responses. T-SCM cells can be expanded by Urolithin A (UA), which is produced by the ...

CELL PRESS2022

The role of eosinophils in breast cancer

Luisa Spisak

Eosinophils are granulocytes and belong to the innate arm of immunity. Eosinophils can be in different basal or activation states and depending on which type of activation is applied, they exert different effector functions. These multi-functional cells ha ...

EPFL2022

Engineering T Cell Trafficking and Function for Enhanced Cancer Immunotherapy

Yuqing Xie

In the past decades, breakthroughs in cancer immunotherapy have led to unprecedented clinical responses in patients with advanced-stage cancers that would otherwise be fatal. However, treatment of many solid organ malignancies with highly immunosuppressive ...

EPFL2022

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Douglas Hanahan, Nadine Fournier, Mélanie Louise Tichet, Krisztian Homicsko, Agnieszka Alicja Chryplewicz, Mohammad Sadegh Saghafinia, Yuqing Xie, Dalya Ataca, Qiqun Zeng, Jeremy Gilles Louis Guillot, Simge Yücel

Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FM ...

American Association for the Advancement of Science2022

Dynamic partitioning of branched-chain amino acids-derived nitrogen supports renal cancer progression

Vassily Hatzimanikatis, Maria Masid Barcon

Metabolic reprogramming is critical for tumor initiation and progression. However, the exact impact of specific metabolic changes on cancer progression is poorly understood. Here, we integrate multimodal analyses of primary and metastatic clonally-related ...

Nature Portfolio2022

Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer

Hatice Altug, Alexander Mathis, George Coukos, David Gfeller, Pedro Romero, Alexandre Harari, Xiaokang Li, Yen-Cheng Liu

CD4 T cells have been implicated in cancer immunity for their helper functions. Moreover, their direct cytotoxic potential has been shown in some patients with cancer. Here, by mining single-cell RNA-seq datasets, we identified CD4 T cell clusters displayi ...

2021

Neutrophils in the era of immune checkpoint blockade

Etienne Meylan, Julien Robert Rémi Faget

The immune checkpoint blockade-based immunotherapies are revolutionizing cancer management. Tumor-associated neutrophils (TANs) were recently highlighted to have a pivotal role in modulating the tumor microenvironment and the antitumor immune response. How ...

BMJ PUBLISHING GROUP2021